Skye Bioscience, INC Form 4 insider transactions

Andrew J. Schwab, a Director and 10% owner of Skye Bioscience, Inc., sold 148,079 shares of common stock on September 22, 2026.

Andrew J. Schwab, a Director and 10% owner of Skye Bioscience, Inc., sold 33,892 shares of common stock on September 16, 2026 for $1.91 per share.

5AM Partners VII, LLC and 7 others reported changes in beneficial ownership of Skye Bioscience, Inc. common stock on September 16, 2026.

Andrew J. Schwab, a Director and 10% owner of Skye Bioscience, Inc., sold 375,840 shares of common stock on August 18, 2026.

5AM Partners VII, LLC and 7 others reported changes in beneficial ownership of Skye Bioscience, Inc. common stock on August 18, 2026.

Punit Dhillon, Chief Executive Officer and a Director of Skye Bioscience, Inc., received 1,090,000 shares of common stock on August 7, 2026.

Director Karen L. Smith acquired 75,000 stock options in Skye Bioscience, Inc. on March 31, 2026.

Skye Bioscience's Chief Scientific Officer, Christopher Twitty, has repriced several stock options, adjusting exercise prices and vesting schedules.

Annalisa Jenkins, a Director at Skye Bioscience, Inc., acquired stock options representing 75,000 shares.

Skye Bioscience Director Deborah H. Charych acquired 75,000 stock options with an exercise price of $0.615.

Paul A. Grayson, a Director at Skye Bioscience, Inc., acquired 75,000 stock options with an exercise price of $0.615.

Andrew J. Schwab, a Director at Skye Bioscience, Inc., has acquired stock options, indicating a potential long-term investment in the company.

Skye Bioscience Chief Operating Officer Tuan Tu Diep reports on stock option repricing and adjustments.

Skye Bioscience's CEO, Punit Dhillon, has repriced several stock options, adjusting exercise prices and vesting schedules.

Skye Bioscience, Inc. Director Andrew J. Schwab was granted 35,000 stock options with an exercise price of $0.82, vesting over one year.

Skye Bioscience, Inc. Director Paul A. Grayson was granted 35,000 stock options with an exercise price of $0.82, vesting over one year.

Skye Bioscience Director Karen L. Smith was granted 35,000 stock options with an exercise price of $0.82, vesting over one year.

Skye Bioscience's Chief Financial Officer, Kaitlyn Arsenault, was granted 125,000 stock options with an exercise price of $0.82, vesting over four years.

Skye Bioscience's Chief Scientific Officer, Christopher Twitty, was granted 150,000 stock options with an exercise price of $0.82.

Skye Bioscience, Inc. Director Deborah H. Charych received a grant of 35,000 stock options with an exercise price of $0.82.

Skye Bioscience Director Annalisa Jenkins was granted 35,000 stock options with an exercise price of $0.82, vesting monthly over one year.

Skye Bioscience's Chief Development Officer, Diep Tuan Tu, was granted 125,000 stock options with an exercise price of $0.82.

Skye Bioscience's Chief Medical Officer, Puneet S. Arora, was granted 125,000 stock options at an exercise price of $0.82 per share.

Skye Bioscience, Inc. CEO Punit Dhillon acquired 280,000 stock options with an exercise price of $0.82, vesting over four years.

Andrew J. Schwab, a Director and 10% owner of Skye Bioscience, Inc., reported the sale of 231,405 shares of common stock in August 2025.

Investment funds associated with 5AM Partners have reported planned sales of Skye Bioscience common shares for August 2025.

Kaitlyn Arsenault, CFO of Skye Bioscience, files an amended Form 4 to correct a typographical error in the previously reported number of shares held after selling shares to cover tax withholding obligations.

Director Andrew J. Schwab acquired 35,000 stock options in Skye Bioscience, Inc. on February 24, 2025.

Kaitlyn Arsenault, CFO of Skye Bioscience, Inc., reports the acquisition of stock options.

Director Annalisa Jenkins acquired stock options in Skye Bioscience, Inc. on February 24, 2025.